Lexeo Therapeutics, Inc.
LXEO- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001907108
In the last 90 days, Lexeo Therapeutics, Inc. insiders filed 0 open-market purchases and 7 sales; 141 institutions reported holding it in 13F filings for Q2 2026, worth $416.9M in total; no superinvestor holds it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $299.8K in total
- 7
- 13F holdersQ2 2026, +5 vs. previous quarter
- 141
- 13F valueReported value at the end of Q2 2026
- $416.9M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding LXEO, Q2 2026
No superinvestor reported holding LXEO at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Lexeo Therapeutics, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Aug 19, 2026 (view filing)5:00 PM ET | Aug 18 | 1 day | Tamayo Louis EdwardChief Financial Officer | SSale | −4.12K | $4.91 | −$20.2K | −4.2%92.9K after | |
| Aug 19, 2026 (view filing)5:00 PM ET | Aug 18 | 1 day | Townsend Richard NolanChief Executive Officer | SSale | −3.35K | $4.95 | −$16.6K | −0.9%374.5K after | |
| Aug 19, 2026 (view filing)5:00 PM ET | Aug 18 | 1 day | Otero Jose ManuelChief Operating Officer | SSale | −1.30K | $4.96 | −$6.46K | −0.9%136.2K after | |
| Jul 1, 2026 (view filing)6:49 PM ET | Jul 1 | Same day | Tamayo Louis EdwardChief Financial Officer | SSale | −4.64K | $4.49 | −$20.8K | −4.6%97.0K after | |
| Jul 1, 2026 (view filing)6:49 PM ET | Jul 1 | Same day | Otero Jose ManuelChief Operating Officer | SSale | −4.67K | $4.48 | −$20.9K | −3.3%137.5K after | |
| Jul 1, 2026 (view filing)6:48 PM ET | Jul 1 | Same day | Bhalla Narinder PalChief Medical Officer | SSale | −22.3K | $4.42 | −$98.6K | −21.3%82.2K after | |
| Jul 1, 2026 (view filing)6:47 PM ET | Jul 1 | Same day | Townsend Richard NolanChief Executive Officer | SSale | −25.9K | $4.48 | −$116.2K | −6.4%377.8K after | |
| May 20, 2026 (view filing) | May 18 | 2 days | Otero Jose ManuelChief Operating Officer | SSale | −1.30K | $5.07 | −$6.60K | −1.0%130.1K after | |
| May 20, 2026 (view filing) | May 18 | 2 days | Townsend Richard NolanChief Executive Officer | SSale | −3.34K | $5.06 | −$16.9K | −1.0%336.8K after | |
| Apr 7, 2026 (view filing) | Apr 6 | 1 day | Townsend Richard NolanChief Executive Officer | SSale | −55.0K | $5.69 | −$312.9K | −13.9%340.1K after | 10b5-1 |
Top 10 13F holders, Q2 2026
The largest institutional positions in Lexeo Therapeutics, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Suvretta Capital Management, LLC | 6,384,200 | $29.7M | 0.62% | +5,134,200+410.7% | Added |
| Affinity Asset Advisors, LLC | 5,807,611 | $27.0M | 1.32% | +757,400+15.0% | Added |
| BlackRock, Inc. | 5,739,455 | $26.7M | 0.00% | +628,584+12.3% | Added |
| Ra Capital Management, L.P. | 5,000,000 | $23.3M | 0.20% | 00.0% | Unchanged |
| Frazier Life Sciences Management, L.P. | 4,824,725 | $22.5M | 0.49% | +400,000+9.0% | Added |
| State Street Corp | 4,354,757 | $20.3M | 0.00% | +786,515+22.0% | Added |
| Vestal Point Capital, LP | 4,320,000 | $20.1M | 0.47% | −155,000−3.5% | Reduced |
| Paradigm Biocapital Advisors LP | 4,175,382 | $19.4M | 0.36% | −2,008,752−32.5% | Reduced |
| Jupiter Topco LLC | 3,954,691 | $18.4M | 0.01% | +3,954,691 | New |
| OrbiMed Advisors LLC | 3,947,850 | $18.4M | 0.35% | +345,400+9.6% | Added |